Isabelle R. C.
- Country
- France
- Department
- Oncology
Research Overview
- Phase 1 Study of STRO-002 and Bevacizumab in Advanced Epithelial Ovarian Cancer, Including Fallopian Tube and Primary Peritoneal Cancers
- Phase 2 Study of ACR-368 and Gemcitabine in Subjects with Endometrial Cancer
- Phase 1/2 Open‑Label Study of Oral GSK5460025A Monotherapy and Combination Therapy Assessing Safety and Efficacy in dMMR/MSI‑H Tumors, colorectal and endometrial cancer
Data & Insights
Has run more than one trial at 222 of 397 partner sites.
Specializations
Gynecologic Oncology
The investigator specializes in the treatment of gynecologic malignancies, with particular emphasis on epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
- Advanced Treatment Approaches
- Platinum-Sensitive Cancers
- Maintenance Therapy Strategies
Clinical expertise extends to innovative therapeutic combinations involving targeted treatments for gynecologic cancers.
Targeted Therapeutics
Focused on developing treatment strategies using targeted therapy combinations, particularly exploring the potential of mirvetuximab soravtansine and bevacizumab in gynecologic cancers.
- Combination Therapy Approaches
- Novel Drug Applications
- Therapeutic Response Assessment
Expertise in evaluating treatment responses using established criteria for solid tumors.
Cancer Maintenance Treatment
Investigates maintenance therapy protocols for patients who have responded to platinum-based chemotherapy, focusing on prolonging treatment benefits.
- Post-Chemotherapy Care
- Disease Progression Prevention
- Long-term Treatment Strategies
Specializes in developing sustained treatment approaches for gynecologic cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.